RE: Big Pharma biggest drugs set to tumble off the patent cliffJanuary 09, 2023 - Striking deals has been a key strategy for BMS in the past few years. By BMS’ estimates, about 50% of its revenue in 2030 will come from acquisitions, starting with the $74 billion takeover of Celgene back in 2019. All those deals helped BMS develop the “scientific, financial and executional skills” to carry out more transactions, BMS Chief Commercialization Officer Chris Boerner said.
"Going forward, business development will continue to be a “top priority” at BMS, and the new products are giving BMS “considerable firepower” to go after external assets, Boerner said."
https://www.fiercepharma.com/pharma/bristol-myers-touts-diversified-portfolio-new-launches-kick-gear-fill-upcoming-patent-cliff